Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Psych MEQs / SAQsPsychopharmacology — lithium

Psych MEQs / SAQs · Psychopharmacology — lithium

Initiating and monitoring lithium in bipolar I with suicide risk (MEQ)

FRANZCP-style MEQ on lithium initiation, TDM, interactions, suicide evidence, and toxicity/EXTRIP.

20 marks20 min1 min readVerification in progress

Target exams

FRANZCPMRCPsychABPNMD-DNB
On this page
Study tools

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 28-year-old woman with bipolar I disorder had a manic episode six weeks ago (now settling on olanzapine). Two prior depressive episodes, one serious suicide attempt last year. eGFR 95, TSH normal, not pregnant, takes PRN ibuprofen for migraine. She asks whether lithium is 'too dangerous' compared with valproate. (i) Justify offering lithium for maintenance and anti-suicide rationale with named evidence. (ii) List pre-start investigations and consent points including sick-day rules. (iii) Outline initiation, 12-hour trough targeting, and a monitoring calendar for levels and organs. (iv) Counsel on ibuprofen and other level-raising interactions. (v) Describe recognition and first-line hospital management of toxicity including when EXTRIP applies. (20 marks)

Model answer

Reveal model answerShowHide

(i) Offer lithium. Long-term RCTs/meta-analyses support lithium for bipolar relapse prevention (Geddes). BALANCE: lithium monotherapy and lithium–valproate combination both beat valproate monotherapy for any mood episode in bipolar I — so valproate alone is not an evidence-equivalent default. Cipriani 2013: lithium reduces suicides and all-cause deaths versus placebo in mood-disorder RCTs — highly relevant after a serious attempt. Frame as gold-standard maintenance with monitoring, not "too dangerous to discuss."[1][2][3]

(ii) Pre-start and consent. Baseline U&E/creatinine/eGFR, TFT, calcium, weight, pregnancy test when relevant, ECG if indicated; full drug history including OTC NSAIDs. Consent: narrow therapeutic index, need for 12-hour troughs and organ bloods, common effects (tremor, polyuria, weight), toxicity red flags, sick-day rules for severe vomiting/diarrhoea/dehydration, contraception/pregnancy plans. Confirm service can deliver monitoring.[4][6][7]

(iii) Initiation and TDM. Start low (e.g. lithium carbonate 250–500 mg/day product-dependent), titrate using clinical response and 12-hour trough levels at steady state. Maintenance scaffold often about 0.6–0.8 mmol/L; individualise. Early denser levels then regular level + eGFR/TFT/calcium calendar per local protocol (principles: more frequent early and after any clearance change).[6][7]

(iv) Interactions. Advise stopping casual ibuprofen; prefer paracetamol for simple analgesia if appropriate; warn that NSAIDs, ACEI/ARB, thiazides and dehydration raise lithium levels and can cause chronic toxicity. Provide written list and GP communication.[5][6]

(v) Toxicity. Stop lithium and precipitants; ABC; IV isotonic saline if volume depleted; serial levels, renal panel, ECG. Charcoal does not bind lithium. EXTRIP: ECTR recommended in severe poisoning and when impaired kidney function coexists with high concentration, or decreased consciousness/seizures/life-threatening dysrhythmias irrespective of level; HD preferred; watch rebound.[5][6]

Psychiatry Fellowship Pro

Continue reading

You have read the opening of this meqs / saq. The complete unit — every section and its primary-source references — is part of the Psychiatry Fellowship fellowship library.

Sign in to continueSee pricing
References7ShowHide
  1. [1]Geddes JR, Burgess S, Hawton K, et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials Am J Psychiatry, 2004.PMID 14754766
  2. [2]Geddes JR, Goodwin GM, Rendell J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial Lancet, 2010.PMID 20092882
  3. [3]Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis BMJ, 2013.PMID 23814104
  4. [4]McKnight RF, Adida M, Budge K, et al. Lithium toxicity profile: a systematic review and meta-analysis Lancet, 2012.PMID 22265699
  5. [5]Decker BS, Goldfarb DS, Dargan PI, et al. Extracorporeal Treatment for Lithium Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup Clin J Am Soc Nephrol, 2015.PMID 25583292
  6. [6]Gitlin M Lithium side effects and toxicity: prevalence and management strategies Int J Bipolar Disord, 2016.PMID 27900734
  7. [7]Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 Pharmacopsychiatry, 2018.PMID 29390205
Psychiatry Fellowship Pro

$29/ monthor $279 / year

The complete Psychiatry Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousInitiating an irreversible MAOI safely in treatment-resistant depression (MEQ)Psychopharmacology — monoamine oxidase inhibitorsNextInitiating and reviewing cognitive enhancers in Alzheimer disease (MEQ)Psychopharmacology — cognitive enhancers